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1Abstract
Background:  Scientists often use a paired comparison of the areas under the receiver operating
characteristic curves to decide which continuous cancer screening test has the best diagnostic
accuracy.  In the paired design, all participants are screened with both tests.  Participants with
unremarkable screening results enter a follow-up period.  Participants with suspicious screening
results and those who show evidence of disease during follow-up receive the gold standard test.
The remaining participants are classified as non-cases, even though some may have occult
disease.  The standard analysis includes all study participants in the analysis, which can create
bias in the estimates of diagnostic accuracy.  If the bias affects the area under the curve for one
screening test more than the other screening test, scientists may make the wrong decision as to
which screening test has better diagnostic accuracy.  We propose a weighted maximum
likelihood bias correction method to reduce decision errors.
Methods:  Using simulation studies, we assessed the ability of the bias correction method to
reduce decision errors.  The simulations compared the Type I error rate and power of the
standard analysis with that of the bias-corrected analysis.  We varied four factors in the
simulation: the disease prevalence, the correlation between screening test scores, the rate of
interval cases, and the proportion of cases who receive the gold standard test.  We demonstrate
the proposed method with an application to a hypothetical oral cancer screening study.
Results:  The amount of bias in the study and the performance of the bias correction method
depend on characteristics of the screening tests and the disease, and on the percentage of study
participants who receive the gold standard test.  In studies with a large amount of bias in the
difference in the full area under the curve, the bias correction method reduces the Type I error
rate and improves power for the correct decision.
Conclusion:  The bias correction method reduces decision errors for some paired screening
trials.  In order to determine if bias correction is needed for a specific screening trial, we
recommend the investigator conduct a simulation study using our software.
2Keywords: cancer screening, differential verification bias, area under the curve, type I error,
power, paired screening trial, receiver operating characteristic analysis
3Background
Paired screening trials are common in cancer screening.  For instance, one of the designs
considered for a planned oral cancer screening study was a paired comparison of the oral tactile
visual exam with the VELscope imaging device 1 .  Two recent breast cancer screening studies 
used a paired design to compare film and digital mammography 2, 3 .  In paired cancer 
screening trials, investigators screen all participants with both screening tests.  Participants with
unremarkable screening test scores on both tests enter a follow-up period.  Participants with
suspicious screening test scores or who show signs and symptoms of disease during the follow-
up period, undergo further workup leading to the gold standard test, biopsy.  The remaining
participants are assumed to be disease-free.  In truth, they may have occult disease.
In the trial by Lewin  2 , the investigators used the standard analysis to compare the fullet al.  
areas under the receiver operating characteristic curves.  The standard analysis includes all
participants, even those whose disease status is not verified with the gold standard test.  Because
some cases are misclassified as non-cases, the receiver operating characteristic curves and the
corresponding areas under the curves may be biased, thus causing decision errors 4 .  We use 
bias in the epidemiological sense of the word as the difference between what the study
investigator  and the , unobservable state of nature 5 .  If the bias is severe enough,observes true  
investigators can detect a difference between screening tests when there is none, or decide that
the tests are different, but conclude incorrectly that the inferior test is superior.  Choosing the
inferior screening test can delay diagnosis of cancer and increase morbidity and mortality.
We propose a bias-corrected hypothesis test to reduce decision errors in paired cancer
screening trials.  Under the assumption that the screening test scores follow a bivariate Gaussian
distribution, conditional on disease status, we use an iterative, maximum likelihood approach to
reduce the bias in the estimates of the mean, variance, and correlation.  The resulting estimates
are then used to reduce bias in the estimates of the diagnostic accuracy of the screening tests.
Screening trials are subject to different biases depending on the choice of reference standard
and analysis plan 6 9 .  Imperfect reference standard bias occurs when the investigator 
4evaluates all study participants with an imperfect reference standard 7, 8, 10 .  Partial 
verification bias occurs if 1) the investigator evaluates only some participants with a gold
standard, 2) the decision to use the gold standard test depends on the screening test outcome, and
3) the investigator only includes participants with gold standard results in the analysis, a
complete case analysis 11 .  Differential verification bias occurs when 1) the investigator uses a 
gold standard test for a portion of participants and an imperfect reference standard for the
remaining participants, 2) the decision to use the gold standard test depends on the results of the
screening test, and 3) the investigator includes data from all participants in the analysis 8 . 
Paired screening trial bias 4 , the focus of our research, is a special case of differential 
verification bias.  Paired screening trial bias occurs in paired screening trials when three
conditions hold: 1) The investigator analyzes data from all the participants 2) the screening tests
are subject to differential verification bias and 3) each screening test has associated with it a
different threshold score that leads to the gold standard test 4 . 
In the following sections we describe the bias correction method and evaluate its performance
by simulation.  In the Methods section, we explain the study design of interest, outline the
assumptions and notation, delineate the bias correction algorithm, and describe the design of the
simulation studies.  In the Results section, we report on the results of the simulation studies and
demonstrate the utility of the method using a hypothetical oral cancer screening study.  Finally,
in the Discussion section, we discuss the implications of our method.
Methods
Study Design
The study design of interest is a paired study of two continuous cancer screening tests.  The
design was considered by Lingen 1  in a planned oral cancer screening trial, and was used in 
two recent breast cancer screening trials 2, 3 .  A flowchart of the study design is shown in 
Figure 1.
We consider the screening studies from two points of view 12 .    We consider the point of
view of the omniscient observer who knows the  disease status for each participant.true   We also
5consider the point of view of the study investigator, who can only see the  results of theobserved
study.
The study investigator determines disease status in two ways:  through follow-up, or through a
definitive method for the ascertainment of disease status.  Any score that exceeds the threshold
of suspicion defined for each screening test triggers the use of a gold standard test.  Cases
identified due to remarkable screening test scores are referred to as .screen-detected cases
Participants with unremarkable screening test scores on both screening tests enter a follow-up
period.  Some participants may show signs and symptoms of disease during the follow-up
period, leading to a gold standard test.  Participants who are diagnosed as cases because of signs
and symptoms during the follow-up period are referred to as .  We refer to theinterval cases
collection of screen-detected cases and interval cases as the observed cases.  Participants with
unremarkable screening test scores who do not show signs and symptoms of disease during the
follow-up period are assumed to be disease-free.
Under the assumption that the gold standard test is 100% sensitive and specific, the study
design described above will correctly identify all non-cases.  However, the design may cause
some cases to be missed.   cases occur when study participants who actually have diseaseMissed
receive unremarkable screening test scores and show no signs or symptoms of disease.
We present a graph of a hypothetical dataset of screening test scores (Figure 2) to illustrate
how the study investigator  disease status.  The axes represent the thresholds ofobserves
suspicion for each screening test.  The study investigator  every case in the gray region,observes
but a smaller portion of cases in the white region.  We can identify the missed cases because we
present this graph from an omniscient point of view.
Standard Analysis
In the standard analysis, the study investigator compares the diagnostic accuracy of the two
screening tests, measured by the full area under the receiver operating characteristic curve.  The
receiver operating characteristic curves are calculated using data from all cases and non-cases
observed in the study. When cases are missed, the study investigator calculates the sensitivity
6and specificity of the screening test incorrectly.  The error in sensitivity and specificity causes
concomitant errors in the area under the curve.  Thus, the  area under the curve canobserved
differ from the  area under the curve.true
The error in sensitivity may be large 4 .  However, the error in specificity is negligible.  Thus, 
our proposed bias correction method only corrects the estimation of the sensitivity and does not
correct specificity. In fact, a specificity correction is typically not possible, because very few
non-cases actually receive the gold standard test.
Assumptions, Definitions, and Notation
We make a series of assumptions.  Let  be the total number of study participants, and  the8 1
prevalence of disease in the population.  Assuming simple random sampling, the number of
participants with disease is , and is distributedQ − !ß 8 
Q µ Ð8ß ÑBinomial . 11  
Let index participants,  index the screening test, and 3 − "ß #ßá ß 8 4 − "ß # 5 − !ß "     
indicate the presence ( ) or absence ( ) of disease.  Let  denote the screening test5 œ " 5 œ ! \345
score for the  participant on the  screening test with  disease status .  For each disease3 4 5th th true
status, ,  and participant , the pair of test scores,  and , are independently and5 3 \ \3"5 3 52
identically distributed bivariate Gaussian random variables with means, , variances, , and. 545 45#
correlation, .35
Let  be the threshold of suspicion for screening test .  All scores above the threshold will+ 44
trigger the use of a gold standard test.  Let  be the event that a participant shows signs andM
symptoms of disease during a follow-up period and .  We assume thatT Ml5 œ " œ  <
T Ml5 œ ! œ !  .
 For screening test , the  is 100 times the number of participants with4 percent ascertainment
disease who score above the threshold on screening test , divided by the total number of4
participants with  disease.observed
7Bias Correction Algorithm
We describe an algorithm to reduce bias in estimates of the area under the curve.  The
algorithm requires four steps.
Step 1. Partition.  The  cases can be stratified into two sets, shown in Figure 2.  Let observed E
(data in the gray area) be the set of  cases with at least one screening test score above itstrue
respective threshold.  Let  (data in the white area) be the set of  cases where the scores onF true
both screening tests fall below their respective thresholds. The percentages of participants with
observed observed disease in sets  and  differ:  all cases of disease in set  are , but only aE F E
fraction of cases are  in set .  We handle the estimation for each set separately, andobserved F
combine the estimates using weighting proportional to the sampling fraction 13; Equation 3.3.1, p. 81 .
Step 2. Maximum Likelihood Estimation.  We obtain maximum likelihood estimates of the
bivariate Gaussian parameters for the cases.  The estimation process follows an iterative method
suggested by Nath 14 .  The method allows unbiased estimation of bivariate Gaussian 
parameters from sample spaces truncated to be convex.  Set  is not a convex set.  To obtainE
convex sets, we further partition the sample space into quadrants , , as shownU 6 − "ß #ß $ß %6  
in Table 1Þ
The starting values for the iteration are the sample statistics for the  cases in eachobserved
quadrant.  From the four quadrant specific estimates, we choose the set that maximizes the log
likelihood of the full bivariate Gaussian distribution with respect to the  data.  We referobserved
to that set as the Nath estimates, denoted by , , , , and  .  Note that the. . 5 5 3s s ss s""ßR #"ßR "ßR# #""ßR #"ßR
5 index is always equal to one since we only estimate parameters for the bivariate Gaussian
distribution of cases.
We require the sample variance as a starting value for the Nath algorithm.  However, we can
only calculate the sample variance for quadrants with two or more observations.  Thus, if  hasU6
only one observation, we do not calculate the quadrant specific estimates for that quadrant.
8Step 3. Weighting.  The Nath estimates are only based on one quadrant of data.  We use the
weighting described below to incorporate data from all quadrants and thereby lower the variance.
We refer to the weighted estimates as the  estimates and use them to calculate thecorrected
corrected areas under the receiver operating characteristic curves.  If either set  or set E F
contain only one observation, we do not conduct the weighting and instead use the Nath
estimates as the .corrected estimates
The Nath estimates are used as inputs for calculating the sampling fraction for sets  and .E F
Define the estimated probability of  asE
   . 2
  
  
- F 3. .5 5s œ "  ß ß
+  + s s
s s s   " #""ßR #"ßR""ßR #"ßR "ßR
Let  if a participant is  to have disease and  otherwise.  For the screen positive5 œ " !w observed
cases, let  be the sample mean,  be the sample standard deviation for screening test ,\ W 445 ßE 45 ßEw w
and be the sample correlation between the screening tests.  For the interval cases, let < \5 ßE 45 ßFw w
be the sample mean,  be the sample standard deviation for screening test , and be theW 4 <45 ßF 5 ßFw w
sample correlation between the screening tests. Let , , and be the weighted. 5 3s s s4"ß[ "ß[#4"ß[
estimates of the mean, variance, and correlation for the screening test scores for the cases.
We derived expressions for the weighted parameter estimates using the conditional covariance
formula 15; Proposition 5.2, p. 348  and the definition of the weighted mean 13; Equation 3.2.1, p. 77 .  We define the estimates as follows:
. - -s œ \  "  \s s ""ß[ ""ßE ""ßF  , 3   
. - -s œ \  "  \s s #"ß[ #"ßE #"ßF  , 4   
5 Z [ .s œ   s#""ß[ " " ""ß[# , 5 
5 Z [ .s œ   s##"ß[ # # #"ß[# , 6   
and
93 5 5 c d . .s œ  s s s s"ß[ ""ß[ #"ß[# #""ß[ #"ß[    7
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d - -œ "  \ \  "  W W <s s    ""ßF #"ßF ""ßF #"ßF "ßF .
Evaluation of Bias Correction
We compared the Type I error and power of the observed corrected true, , and  analyses.  For
the observed observed analysis, we used the  disease status as inputs for the paired comparison of
the diagnostic accuracy of the screening tests.  The  analysis replicates the standardobserved
analysis performed by the study investigator of a cancer screening trial.  For the corrected
analysis, we used the proposed bias correction approach.  Finally, both the  andobserved
corrected true true analyses were compared to the  analysis.  The  analysis assumes that the study
investigator knows the  disease status of every participant.true
For each analysis, we tested the null hypothesis that there is no difference in the areas under
the receiver operating characteristic curves.  We calculated the areas under the binormal receiver
operating characteristic curves 16; p. 122 .  We then calculated the variance of the difference in
the areas under the curves and conducted a hypothesis test using the method of Obuchowski and
McClish 17 .    Ethically, we can only conduct a screening trial if we have clinical equipoise, ,i.e.
if we do not have evidence to favor one screening strategy over the other.  Thus, we used a two-
sided hypothesis test.
To assess screening , we compared the Type I error and power for thetest performance
observed corrected true,  and  analyses, .  Power is the probability that we reject the null
hypothesis.  When the hypothesis test detects a difference between the screening tests, the study
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investigator uses the estimates of diagnostic accuracy to decide which screening test to
implement.  However, the estimates of diagnostic accuracy can be biased.  Consequently, even
though the study investigator correctly concludes that there is a difference between the two
screening tests, the investigator may incorrectly choose to implement the screening test with the
lower diagnostic accuracy.  To quantify the decision error, we divided power into the correct
rejection fraction wrong rejection fraction. correct rejection fraction and the   The  is the
probability that the hypothesis test rejects and the screening test with the larger  areaobserved
under the curve is the screening test with larger  area under the curve.  The true wrong rejection
fraction is the probability that the hypothesis test rejects but the screening test with the larger
observed true area under the curve is the screening test with the smaller  area under the curve.
Design of Simulation Studies under the Gaussian Assumption
We conducted simulations under the assumptions listed in Assumptions, Definitions, and
Notation.  We considered two states of nature; one where the null hypothesis holds and one
where the alternative hypothesis holds.  When the null holds, the two screening tests have the
same diagnostic accuracy.  When the alternative holds, the screening tests have different
diagnostic accuracies.
The simulation studies varied four factors: 1) the disease prevalence, 2) the proportion of
cases that exhibit signs and symptoms of disease during follow-up, 3) the correlation between
Test 1 and 2 scores, and 4) the thresholds that trigger a gold standard test.  The four factors
change the amount of bias in the estimates of the diagnostic accuracy of each screening test.  In
addition, the factors change the number and proportion of cases.  For brevity, we doobserved 
not present the correlation study results in this manuscript.  The correlation between the
screening tests had a negligible effect on the performance of the bias correction method.
For each combination of parameter values, we simulated paired screening test scores and a
binary indicator of  disease status.  Based on the described study design, we deduced thetrue
observed true observed corrected disease status.  We calculated the , , and  areas under the curves
and assessed the results of the simulation study using the metrics introduced in the Evaluation of
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Bias Correction section.  We used 10,000 realizations of the simulated data to ensure that the
error in the estimation of probabilities occurred in the second decimal place.
Design of Non-Gaussian Simulation Studies
We conducted a second set of simulation studies to examine the robustness of the bias
correction method to deviations from the Gaussian assumption.  We considered two possible
deviations:  zero-weighted data, which corresponds to screening test scores with zero values, and
a multinomial distribution, which corresponds to reader preferences for a subset of the possible
screening test scores.  We evaluated the performance of the bias correction method as described
in the Evaluation of Bias Correction section.
To generate the zero-weighted data where the occurrence of zeroes is correlated between the
two screening tests, we generated two sets of correlated Bernoulli random variables, one for
cases and one for non-cases, so that the probability that the score on Test 1 is zero is , the:"5
probability that the score on Test 2 is zero is  and the probability that both screening test:#5
scores are zero is .  If the Bernoulli random variable was one, we replaced the associated;5
screening test score with a zero.  Otherwise, the screening test score remained as it was.  We set
: !Þ!" !Þ*!45  equal to a range of values between  and , creating a series of datasets.  The marginal
probabilities put constraints on the possible values for  18 .  We set  to the median allowed; ;5 5 
agreement for each pairing of .:45
To generate the multinomial data, we binned the bivariate Gaussian data.  We created a series
of datasets, each with a different bin size.  The bin sizes were , , , , and  times the"Î"! "Î# " # &
variance.  We set the disease prevalence to  (low),  (medium) and  (high).!Þ!" !Þ"% !Þ#%
Results
Effect of Disease Prevalence
C disease prevalence affects both the case and non-case case sample size.  In turn,hanging the 
this changes the number of observations used to calculate sensitivity and specificity, which
affects the Type I error rate and power of the analysis.
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Choice of Parameter Values.  The diagnostic accuracy of the screening tests are similar to
those found in the study by Pisano  3 .  When the null holds, we fixed the  area underet al.   true
both curves to be the alternative holds, we fixed the  area under the curve to be!Þ().  When true
!Þ() !Þ(% !Þ!%Þ for Test 1 and  for Test 2 for a  difference of   The sample size was fixed attrue
&!ß !!! !Þ"! and the rate of signs and symptoms at .  The thresholds of suspicion were set to
confer a large degree of paired screening trial bias.
We varied the disease prevalence between  and .  The choice reflects cancer rates!Þ!" !Þ#%
seen in published cancer studies (prevalence of prostate cancer in Tobago men aged 70-79 is
0.28 in 19 ; rate of breast cancer i  s roughly  per  in 2  and 3 ; prevalence of oral lesions' "!!!    
is  in 20 ; prevalences of all major cancers conditional on age and gender fall between  and!Þ"% ! 
!Þ"( per SEER Tables 4.25, 5.15, 15.27, 16.21, 20.27, 23.15 21 ). 
Type I Error.  As shown in panel A of Figure 3, in the presence of paired screening trial bias,
the  Type I error rate ranges between  and .  The  Type I error rateobserved corrected!Þ!' !Þ**
ranges between  and .  Higher disease prevalence has higher Type I error rates.!Þ!$ !Þ!)
Power.  In panels B and C of Figure 3, the analysis   corrected has a high correct rejection
fraction across all disease prevalences likely to be encountered in a cancer screening study.  The
correct rejection fraction ranges between  and .  By contrast, the !Þ&) !Þ*' observed analysis often
wrongly concludes that the worst screening test is best.  For the example shown, the correct
rejection fraction for the  analysis is zero while the wrong rejection fraction rangesobserved
between  and .!Þ)' "Þ!!
Effect of the Rate of Signs and Symptoms
When the rate of signs and symptoms is low, there is a higher potential for occult disease and,
hence, error in the estimates of diagnostic accuracy.
Choice of Parameter Values.  We defined the fixed parameter values as in the Effect of Disease
Prevalence section.  We varied the rate of signs and symptoms across a range of clinically
relevant values.  In cancer screening, the rate of signs and symptoms is not typically reported,
but can be approximated using surrogates.  In the trial by Lewin et al.  2 , we can use the
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proportion of interval cancers out of all  cancers as an estimate of the largest possibleobserved
rate of signs and symptoms.  An earlier breast cancer screening trial by Bobo, Lee and Thames 22 evaluated the performance of clinical breast exams for early identification of breast cancer.
If we assume an abnormal clinical breast exam is the same as showing signs and symptoms of
disease, then having an abnormal breast exam but a benign mammogram is akin to a woman
screening negative on mammography but then showing signs and symptoms of disease.  Based
on these surrogates, the approximate values for the rate of signs and symptoms were  2!Þ""   and
!Þ!& 22 .    We chose a range of  to  for our simulation studies.! !Þ#!
Type I Error.  In panel A of Figure 4, Type I error declines with increasing rate of signs and
symptoms.  The Type I error rate of the  analysis is below nominal at low diseasecorrected
prevalence, and ranges from  to  at medium and high disease prevalence. Type I error!Þ!$ !Þ"%   
rate of the  analysis ranges between  and at low disease prevalence, and  toobserved !Þ!& !Þ!( !Þ((
"Þ!! at medium and high disease prevalence.
Power.  In panels B and C of Figure 4, increasing the rate of signs and symptoms improves the
correct rejection fraction.  The correct rejection fraction for the  analysis is  at lowtrue !Þ((
disease prevalence and  at medium and high disease prevalence.  The correct rejection"Þ!!
fraction of the corrected analysis ranges from  to  at low disease prevalence and  to!Þ&' !Þ&* !Þ(#
!Þ*( at medium and high disease prevalence.  The analysis has a correct rejectionobserved 
fraction of zero, while the wrong rejection fraction ranges from  to .  Under the extreme!Þ&" "Þ!!
bias conditions of the simulation, the study investigator using the  results will eitherobserved
incorrectly decide that the worst screening test is best, or conclude there is no difference between
the two screening tests.
Effect of Percent Ascertainment
The threshold of suspicion for each screening test determines what percentage of cases receive
the gold standard test.  We chose a threshold for each screening test that corresponds to around
15%, 50% and 80% ascertainment.  Percentages are approximate because the case numbers are
discrete.
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Paired screening trial bias occurs when the percent ascertainment is different for the two
screening tests.  When the percent ascertainment is equivalent for the two screening tests,
estimates of diagnostic accuracy for each screening test may still be subject to differential
verification bias.  However, since each test is biased by the same amount, the difference in the
areas under the curves will remain unchanged.
Table 2 shows the Type I error of the   and  analyses for a selection oftrue observed corrected,
percent ascertainment levels.  We do not discuss the power results since the Type I error of the
observed analysis is so high and power is bounded below by Type I error rate.
Choice of Parameter Values.  We defined the fixed parameter values as in the Effect of Disease
Prevalence.  We chose values for the thresholds that allowed the amount and source of the bias
(Test 1 or Test 2) to vary across a wide range of possible screening study scenarios.
Type I Error.  In general, when the study is biased, the Type I error rate of the observed
analysis is too high (  to ).  !Þ#$ "Þ!! The Type I error rate of the  analysis is closer tocorrected
nominal than that of the  analysis, but is also too high (  to ).  For the pairingsobserved !Þ"# !Þ*&
with no paired screening trial bias, the  analysis has lower than nominal Type I errorobserved
rates ( ) while the  analysis has Type I error rates up to .  When the percent!Þ!# !Þ#'corrected
ascertainment is high ( ) for both screening tests, the Type I error rate of the )!Î)! corrected
analysis is below nominal.
Robustness to Non-Gaussian Data
Although the bias correction method was developed under an assumption that the data were
bivariate Gaussian, screening data may not follow the Gaussian distribution.  Multinomial and
zero-weighted data are common in imaging studies.  Often, in imaging studies, readers give the
image a score of zero to indicate that no disease is seen, resulting in a data set where multiple
values are zero.  In addition, reader preferences for a subset of scores can produce a multinomial
data set.
The bias correction method can still be used if data are multinomial or zero-weighted.  For
multinomial data, the method performs well when the bins for the multinomial are scaled to less
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than half the variance.  For zero-weighted data, the bias correction algorithm can reduce decision
errors when up to 30% of the non-cases and 1% of the cases receive a score of zero.  The study
investigator can obtain a rough estimate of the percentage of cases that receive zero scores from
the published rate of interval cancers.
Demonstration
Figure 5 shows the receiver operating characteristic curves for a hypothetical oral cancer
screening trial similar to that considered by Lingen 1 .  One of the designs considered by Lingen 
was a paired trial comparing two oral cancer screening modalities:  1) examination by a dentist
using a visual and tactile oral examination, and referral for biopsy only for frank cancers (Test
1); and 2) examination by a dentist using a visual and tactile oral exam, a second look with the
VELscope oral cancer screening device, and stringent instructions to biopsy any lesion detected
during either examination (Test 2).
We could find no published oral cancer screening trials of paired continuous tests.  Instead, we
chose parameter values from a breast cancer screening study 3  and an oral cancer screening 
demonstration study 20 .  We fixed the sample size at 50,000 3  and the rate of visible lesions at   
0.1 (rate of suspicious oral cancer and precancerous lesions reported in 28 studies between 1971
and 2002 ranges from 0.02 to 0.17, Table 6, 20 ).  We approximated the disease prevalence as 
!Þ!" based on the number of Americans with cancer of the oral cavity and pharynx 21  and the 
2011 population estimate from the U.S. Census Bureau 23 .    For the purposes of the illustration,
the  areas under the curves for Test 1 and Test 2 were fixed at  and , respectively,true !Þ(( !Þ("
similar to the areas under the curves reported for digital and film mammography 3 .    In truth, we
have no data to support the superiority of the visual tactile oral exam over the visual tactile oral
exam plus scope.
The trial by Pisano  compared digital and film mammography 3 .  Since the recall rateet al.  
for both modalities was 8.4%, the trial was unlikely to be biased.  In the hypothetical oral cancer
screening trial, however, we posit that there would be a large difference in the percent
ascertainments for each screening modality.  In the first arm, the dentist only recommends
16
biopsy for participants with highly suspicious lesions.  Thus, we fixed the percent ascertainment
to be very low, only 0.01%.  The oral pathologist recommends biopsy for almost any lesion so
we set the percent ascertainment at 97%.  The large difference in percent ascertainment between
the two screening tests creates extreme paired screening trial bias.
Under conditions of extreme bias, our bias correction method performs well, as shown in
Figure 5.  The  difference in the areas under the curves is   the true observed!Þ!' (p = ),!Þ!!"
difference is  , and the  difference is  .  In the !Þ!' !Þ!'(p = ) (p = )!Þ!!& !Þ!!"corrected
observed analysis, the receiver operating characteristic curves have the opposite orientation to
the true state of nature.  The  analysis removes the bias and the curves are realignedcorrected
with the true state of nature.
In reality, the study investigator would not know which analysis had results closest to the
truth.  To validate our choice of analysis, we simulated the hypothetical study design using the
parameter values specified above.  The simulated Type I error rate of the corrected analysis is
below nominal at , while the Type I error rate of the observed analysis is above nominal at!Þ!$
!Þ!' !Þ&).  The correct rejection fraction of the bias-corrected analysis is , while that of the
observed analysis is zero.  In fact, using the observed analysis, the study investigator would
wrongly conclude that Test 2 is superior to Test 1 86% of the time.  Based on this simulation, we
would recommend the study investigator use the bias correction method to correct the results of
the hypothetical oral cancer screening study.
Discussion
We could find no other methods that attempted to ameliorate paired screening trial bias for
paired cancer screening studies that use the difference in the full area under the curve as a metric.
Re-weighting, generalized estimating equations, imputation and Bayesian approaches have been
proposed to reduce the effect of partial verification bias , 11, 24 29 .  Maximum likelihood e.g. 
methods 30  and latent class models 31  have been proposed to estimate diagnostic accuracy in   
the presence of imperfect reference standard bias.
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The amount of bias in the study and the performance of the bias correction method depend
on fourteen factors:  the means, variances, and correlation of the case and non-case test scores,
the disease prevalence, the rate of signs and symptoms, and the percent ascertainment for each
screening test.  After careful analysis of over  combinations of the parameter values, we"(!ß !!!
were unable to determine a definitive pattern upon which to base recommendations for using the
standard analysis versus a bias-corrected approach.
In order to determine if bias correction is indicated for a specific screening trial, we
recommend the investigator conduct a simulation study similar to those described in the
manuscript.  The simulation software will be made available at www.samplesizeshop.com.  The
software will simulate Type I error rate and power for both the standard and bias-corrected
analyses.  The study investigator should choose the analysis that has the Type I error rate closest
to the nominal level and the highest correct rejection fraction.
The software will request that the study investigator specify the values of each of the
fourteen factors.  Estimates can be based on previous studies or auxiliary information.  For
instance, the rate of signs and symptoms is usually not described in the literature.  In the Results
section, we calculated an estimate for the rate of signs and symptoms using surrogate values
published in two breast cancer screening studies.  When convincing values cannot be found, the
study investigator can conduct a sensitivity analysis using a range of values to see how strongly
that parameter affects the choice of analysis.
In this article, we treat the prevalence of disease as a fixed feature of our study population.
However, the disease prevalence may be higher or lower for different subgroups of the
population.  For instance, in the DMIST study, women younger than 50 years of age had a much
lower prevalence of invasive breast carcinoma than women greater than 50 years of age 3 .  At 
this time, the method does not allow for a heterogeneous case mixture.  To allow for differences
in disease prevalence in the study population, the study investigator can stratify participants into
subgroups with a homogeneous disease prevalence.  The investigator would then conduct
separate analyses for each subgroup.
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In some instances, both the standard analysis and the corrected analysis will have higher than
nominal Type I error rates.  In this case, we recommend that investigators avoid using a paired
screening study design.  Another option would be to randomize study participants to one of two
possible screening modalities.  However, a randomized trial is inefficient relative to a paired
screening trial, and may still be subject to differential verification bias.  A more clinically useful
endpoint may be to consider mortality, as was done in the National Lung Screening Trial
(NLST) 32 .  Unlike receiver operating characteristic analysis, mortality trials such as the NLST 
are not vulnerable to paired screening trial bias, or verification bias in general.
 The bias correction method is a maximum likelihood method.  Thus, the accuracy of the
estimation depends on the number of cases.  We do not recommend using the method for studies
with a very small number of cases ( ), and interval cases ( 5). &!! 
This paper provides two contributions to the statistical literature.  First, we describe a method
to correct for paired screening trial bias, a bias which has not been addressed by other correction
techniques.  Due to the increasing use of continuous biomarkers for cancer (see, , 33 ), ae.g.  
growing number of screening trials have the potential to be subject to paired screening trial bias.
The proposed method will counteract bias in the paired trials and allow investigators to compare
screening tests with fewer decision errors.  Second, we introduce an important metric for
evaluating the performance of bias correction techniques, that of reducing decision errors.  We
recommend that every new bias correction method be evaluated with a study of Type I error and
power.
Conclusions
The proposed bias correction method reduces decision errors in the paired comparison of the
full area under the curve of screening tests with Gaussian outcomes.  Because the performance of
the bias correction method is affected by characteristics of the screening tests and the disease
being examined, we recommend conducting a simulation study using our free software before
choosing a bias-corrected or standard analysisÞ
19
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Table 1.  Quadrant definitions.
Quadrant Name Definition
U B   + à B   +
U B   + à B  +
U B  + à B   +
U B  + à B  +
" 3"5 " 3#5 #
# 3"5 " 3#5 #
$ 3"5 " 3#5 #
% 3"5 " 3#5 #
    
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Table 2.  Effect of percent ascertainment on the Type I error rate.  Type I error rates are
calculated over  repetitions of the data for the hypothesis test of a difference in the full"!ß !!!
areas under the curves.  The nominal Type I error is fixed at .!Þ!&
Paired Percent
Screening Ascertainment
Trial Bias? (Test 1 / Test 2)
Disease
Prevalence True Observed Corrected
!Þ!" "&Î&!
!Þ!" "&Î)!
!Þ!" &!Î)!
!Þ!" !Þ)* !Þ$'
!Þ!# !Þ*& !Þ#&
!Þ!" !Þ#$ !Þ"#
!Þ"% "&Î&! !Þ!# "Þ!! !Þ)#
!Þ"% "&Î)! !Þ!# "Þ!! !Þ'!
!Þ"% &!Î)! !Þ!# "Þ!! !Þ#!
!Þ#% "&Î&!
!Þ#% "&Î)!
!Þ#% &!Î)
Yes
! !Þ!# "Þ!! !Þ%!
!Þ!# "Þ!! !Þ*&
!Þ!# "Þ!! !Þ*"
!Þ!" "&Î"& !Þ!" !Þ! !Þ
!Þ!" &!Î&! !Þ! !Þ!# !Þ
!Þ!" )!Î)! !Þ! !Þ! !Þ
!Þ"% "&Î"&
!Þ"% &!Î&!
!Þ"% )!Î)
1 12
2 2 18
2 23
No
! !Þ! !Þ! !Þ
!Þ! !Þ! !Þ
!Þ!# !Þ!# !Þ
!Þ#% "&Î"& !Þ! !Þ! !Þ
!Þ#% &!Î&! !Þ!# !Þ!# !Þ
!Þ#% )!Î)! !Þ! !Þ! !Þ
2 2 26
2 2 03
14
2 2 26
2 2 04
14
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Figure 1.  Flowchart of a paired trial of two continuous screening tests.  The flowchart
culminates in the study investigator's observation of the disease status of the participant.
Signs and 
symptoms?
Screen
positive on 
one or both 
tests?
Gold Standard Test
Follow-Up
No observed diseaseObserved disease
Yes
No
No
Yes Confirmed 
disease?
Yes No
Screening by both tests
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Figure 2.  Hypothetical data for a paired screening trial.  Paired screening test scores are for the
non-cases, screen-detected cases, interval cases, and missed cases in a hypothetical screening
study comparing two continuous screening tests.
30
Figure 3.  Effect of disease prevalence on Type I error rate and power.  The nominal Type I
error was fixed at   Graphs show the proportion of times the hypothesis test rejects and A)!Þ!&Þ
the null holds, B) the alternative holds and the conclusion of the hypothesis test agrees with the
true state of nature, or C) the alternative holds but the conclusion of the hypothesis test is
opposite the true state of nature.
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Figure 4.  Effect of the rate of signs and symptoms on Type I error rate and power.  The nominal
Type I error was fixed at .  Panels A, B, and C are as in Figure 3.!Þ!&
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Figure 5.  Receiver operating characteristic curves for a hypothetical oral cancer screening
study.  The study is subject to paired screening trial bias.  The  areas under the curves fortrue
Test 1 and Test 2 are and , respectively, for a difference of .  The !Þ(( !Þ(" !Þ!'true observed
difference is , with the  difference at . !Þ!' !Þ!'corrected
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